Perseus PCI President Buddy Long Announces Opening of Cayman Islands Cancer Clinic

Share Article

Buddy Long, president of Perseus PCI, has announced the opening of the company’s state-of-the art Cayman Islands Cancer Clinic.

Buddy Long, president of Perseus PCI, has announced the opening of the company’s state-of-the art Cayman Islands Cancer Clinic.

The new clinic, which will provide advanced treatment for solid-tumor cancers, will be the first in the world to apply cancer immunotherapeutics licensed by and principally based on the work of world-renowned biomedical scientist Dr. Thomas Wagner.

Dr. Sook Yin MD will serve at the new Perseus Caymans Clinic as treating physician for personalized patient care plans coordinated throughout the treatment process by a medical team of U.S.-based and licensed physicians who will evaluate each case for eligibility and function. Members of the U.S. team are also licensed to practice in the Cayman Islands. Dr. Yin earned her medical degree and specialty certifications in Great Britain, serving her internship at the largest and busiest hospital in Belfast, Northern Ireland.

Said Long: “Dr. Yin is a masterful clinician. She is the perfect partner with the right focus on patient focused care to deliver Dr. Wagner’s research breakthroughs, which go back decades and helped launch gene-based medicine and other aspects of the biotech industry. The Cayman Islands are a British Overseas Territory and an international crossroads. We are thrilled to choose the Cayman Islands as the site for our first clinic and to offer the very first applications of this research breakthrough to patients worldwide who suffer from advanced forms of life-threatening solid-tumor cancers.”

Dr. Wagner has held prestigious faculty and research positions at Cornell University College of Medicine, The Sloan Kettering Institute for Cancer Research, Ohio University, Cambridge University, Ohio Edison Biotechnology Institute, Clemson University and the Greenville Hospital System University Medical Center. He has published more than 250 books and scientific papers in highly respected peer-reviewed biomedical journals, and holds more than 50 patents.

Added Long: “Dr. Wagner is one of the most famous and respected biochemists in the world. He and his work have attracted more than $50 million in research funding. Since the 1970s, Dr. Wagner has been a partner or a principal investigator for any number of major discoveries in the conformational changes in DNA associated with gene expression. His research, done in collaboration with some of the finest doctors and clinicians in the world, has advanced embryonic microsurgery and the methods in molecular biology that are used to assemble recombinant DNA molecules and direct their replication within host organisms.”

More than 30 years ago, Dr. Wagner directed the first team of scientists to develop methods for transferring functional genes between animal species, using recombinant DNA for the first time to produce transgenic animals, and he was among the first to isolate and maintain embryo-derived stem cell populations – techniques that have since radically transformed transplant biology and introduced personalized medicine.

Dr. Wagner was also a pioneer in developing vehicles for cell-based gene therapy in 1987 and was the principal developer of a highly efficient cytoplasmic T7 gene therapy vector in 1993, which achieved for the first time rapid and high levels of gene expression in cancer cells and tissues.

Since 1998, Dr. Wagner’s research has focused exclusively on the application of modern molecular and cellular biology to the development of new therapies for the treatment of cancer. He served as Director for the Oncology Research Institute of Greenville Hospital System, which is a national, award-winning leader in effectively applying advanced medical technology in the fight against cancer. Dr. Wagner was also a Director of Eternal Technologies Group Inc., based in Beijing, China, which develops, manufactures and markets advanced medical equipment and technologies used in the detection and prevention of breast cancer.

About Perseus PCI

Perseus PCI is a cancer treatment center headquartered in the Cayman Islands. Perseus provides an effective treatment approach for solid-tumor cancers that produces little to no side effects and can be an alternative to chemotherapy and radiation. The therapy, which uses the natural immune system, is easily administered by injection under the skin surface once a month for four months. This technology’s safety and effectiveness has been proven in US FDA sanctioned trials. The US approval process is ongoing, but this treatment has been approved for manufacture and administration by the Health Practice Commission of the Cayman Islands.

The therapy offered by Perseus is a dendritic cell-based immunotherapy, which has already been shown to be effective against melanoma, renal cell carcinoma and neuroblastoma tumors. Dendritic cells can be stimulated to activate a cytotoxic (killer) response toward the particular tumor. The patient’s dendritic cells are loaded with all of the patient’s tumor cell components to make the vaccine. When the vaccine is administered to the patient, the dendritic cells, a type of antigen-presenting cell, present the tumor antigen to the effector lymphocytes (CD4+ T cells and CD8+ cells), which initiates a cytotoxic response against the tumor cells.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Alexis Delee
Follow us on
Visit website

Media